

Mario Cottone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7910433/publications.pdf>

Version: 2024-02-01

112
papers

8,104
citations

109137

35
h-index

48187

88
g-index

112
all docs

112
docs citations

112
times ranked

11478
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1118-1125.	9.4	2,284
2	Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Meta-Analysis of Randomized Controlled Trials. <i>Radiology</i> , 2002, 224, 47-54.	3.6	784
3	Mortality in patients with coeliac disease and their relatives: a cohort study. <i>Lancet, The</i> , 2001, 358, 356-361.	6.3	553
4	Smoking habits and recurrence in Crohn's disease. <i>Gastroenterology</i> , 1994, 106, 643-648.	0.6	417
5	Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-tumor Necrosis Factor Therapy for Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 30-35.	2.4	316
6	No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. <i>Journal of Hepatology</i> , 1995, 22, 522-526.	1.8	289
7	Radiofrequency Thermal Ablation vs. Percutaneous Ethanol Injection for Small Hepatocellular Carcinoma in Cirrhosis: Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2009, 104, 514-524.	0.2	239
8	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. <i>Gastroenterology</i> , 1995, 108, 345-349.	0.6	197
9	Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children. <i>Clinical Chemistry</i> , 2003, 49, 861-867.	1.5	192
10	Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein. <i>Journal of Hepatology</i> , 1994, 21, 1029-1034.	1.8	171
11	Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. <i>Gastroenterology</i> , 1992, 103, 363-368.	0.6	132
12	The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: The use of tumor necrosis factor-alpha antagonist therapy in Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2011, 43, 1-20.	0.4	125
13	Occult Hepatitis B and Infliximab-induced HBV Reactivation. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 508-509.	0.9	123
14	Asymptomatic hepatocellular carcinoma in Child's A cirrhosis. <i>Gastroenterology</i> , 1989, 96, 1566-1571.	0.6	115
15	Crohn's Disease: A Comparative Prospective Study of Transabdominal Ultrasonography, Small Intestine Contrast Ultrasonography, and Small Bowel Enema. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 139-145.	0.9	115
16	Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trial. <i>Gastroenterology</i> , 1999, 116, 521-526.	0.6	113
17	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. <i>Gastroenterology</i> , 2008, 135, 1500-1509.	0.6	84
18	Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases. <i>European Journal of Internal Medicine</i> , 2013, 24, 385-392.	1.0	74

#	ARTICLE	IF	CITATIONS
19	Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. <i>Digestive Diseases and Sciences</i> , 1988, 33, 47-51.	1.1	71
20	Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 9675.	1.4	70
21	Mesalamine and relapse prevention in Crohn's disease. <i>Gastroenterology</i> , 2000, 119, 597.	0.6	68
22	Efficacy and safety of endoscopic balloon dilation of symptomatic intestinal Crohn's disease strictures. <i>Digestive and Liver Disease</i> , 2011, 43, 121-125.	0.4	68
23	Mortality and causes of death in celiac disease in a Mediterranean area. <i>Digestive Diseases and Sciences</i> , 1999, 44, 2538-2541.	1.1	67
24	Intestinal Permeability and Genetic Determinants in Patients, First-Degree Relatives, and Controls in a High-Incidence Area of Crohn's Disease in Southern Italy. <i>American Journal of Gastroenterology</i> , 2005, 100, 2730-2736.	0.2	66
25	Early post-operative endoscopic recurrence in Crohn's disease patients: Data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1217-1221.	0.6	53
26	Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 681-686.	0.6	52
27	Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestive and Liver Disease</i> , 2017, 49, 604-617.	0.4	47
28	Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. <i>Rheumatology</i> , 2010, 49, 2076-2083.	0.9	43
29	Gastrointestinal lesions associated with spondyloarthropathies. <i>World Journal of Gastroenterology</i> , 2009, 15, 2443.	1.4	42
30	Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2017, 49, 338-358.	0.4	42
31	Cancer in Crohn's Disease patients treated with infliximab: A long-term multicenter matched pair study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 758-766.	0.9	41
32	Psoriasis and Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2019, 37, 451-457.	0.8	41
33	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. <i>Digestive and Liver Disease</i> , 2014, 46, 579-589.	0.4	40
34	Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2013, 45, 986-991.	0.4	38
35	Mesalazine for the treatment of inflammatory bowel disease. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1669-1678.	0.9	35
36	Complete Clinical Remission after High-Dose Immune Suppression and Autologous Hematopoietic Stem Cell Transplantation in Severe Crohn's Disease Refractory to Immunosuppressive and Immunomodulator Therapy. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 892-894.	0.9	32

#	ARTICLE	IF	CITATIONS
37	Treatment of Small Hepatocellular Carcinoma With Percutaneous Ethanol Injection: A Validated Prognostic Model. <i>American Journal of Gastroenterology</i> , 2000, 95, 2921-2927.	0.2	31
38	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 89-98.	1.4	31
39	Familial Occurrence of Inflammatory Bowel Disease in Celiac Disease. <i>Inflammatory Bowel Diseases</i> , 2003, 9, 321-323.	0.9	30
40	Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?. <i>Current Drug Targets</i> , 2011, 12, 1396-1405.	1.0	30
41	Natural history of cytomegalovirus infection in a series of patients diagnosed with moderate-severe ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2011, 17, 633.	1.4	27
42	Relationship between site of disease and familial occurrence in Crohn's disease. <i>Digestive Diseases and Sciences</i> , 1997, 42, 129-132.	1.1	25
43	FAMILIAL ASSOCIATION OF CROHN'S AND COELIAC DISEASES. <i>Lancet, The</i> , 1989, 334, 338.	6.3	23
44	The Role of CARD15 Mutations and Smoking in the Course of Crohn's Disease in a Mediterranean Area. <i>American Journal of Gastroenterology</i> , 2008, 103, 649-655.	0.2	23
45	Severe Cutaneous Psoriasis After Certolizumab Pegol Treatment: Report of a Case. <i>American Journal of Gastroenterology</i> , 2009, 104, 2867-2868.	0.2	23
46	Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter experience of compassionate use. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1168-1170.	0.9	21
47	Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IBD study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 291-300.	0.6	21
48	Oral lichen planus after certolizumab pegol treatment in a patient with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 173-174.	0.6	21
49	Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-7.	0.6	21
50	Ultrasonographic and radionuclide detection of hepatocellular carcinoma in cirrhotics with low alpha-fetoprotein levels. <i>Cancer</i> , 1984, 54, 2924-2926.	2.0	20
51	Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). <i>Drugs and Aging</i> , 2020, 37, 383-392.	1.3	20
52	Could JC virus provoke metastasis in colon cancer?. <i>World Journal of Gastroenterology</i> , 2014, 20, 15745.	1.4	20
53	Postoperative maintenance therapy for inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 377-381.	1.0	19
54	Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-11.	0.7	19

#	ARTICLE	IF	CITATIONS
55	Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: Survival rate and prognostic factors. <i>Digestive and Liver Disease</i> , 2010, 42, 515-519.	0.4	17
56	Medical management of Crohn's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2505-2525.	0.9	17
57	Factors Affecting Clinical and Endoscopic Outcomes of Placebo Arm in Trials of Biologics and Small Molecule Drugs in Ulcerative Colitis: A Meta-Analysis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 987-997.	0.9	17
58	The relationship between heritability and smoking habits in Crohn's disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 3171-3175.	0.2	16
59	The Addition of an Immunosuppressant After Loss of Response to Anti-TNF α Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 394-401.	0.9	16
60	A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1292-1298.	0.4	16
61	A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis. <i>Digestive and Liver Disease</i> , 2020, 52, 1461-1466.	0.4	16
62	Adalimumab Induction for Crohn's Disease. <i>Gastroenterology</i> , 2006, 130, 1929.	0.6	15
63	The Role of Portal Vein Thrombosis in the Clinical Course of Inflammatory Bowel Diseases: Report on Three Cases and Review of the Literature. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-7.	0.7	15
64	Is Epstein-Barr virus infection associated with the pathogenesis of microscopic colitis?. <i>Journal of Clinical Virology</i> , 2017, 97, 1-3.	1.6	15
65	Burden of Crohn's disease: economics and quality of life aspects in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 209.	0.7	13
66	Physicians' Knowledge and Application of Immunization Strategies in Patients with Inflammatory Bowel Disease: A Survey of the Italian Group for the Study of Inflammatory Bowel Disease. <i>Digestion</i> , 2020, 101, 433-440.	1.2	13
67	Investigational agents for Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 1147-1159.	1.9	12
68	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 175-184.	1.4	12
69	Familial aggregation of inflammatory bowel disease in a Mediterranean area. <i>European Journal of Epidemiology</i> , 1996, 12, 205-210.	2.5	11
70	Infliximab and ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 401-408.	1.4	11
71	Adalimumab in steroid-dependent Crohn's disease patients: Prognostic factors for clinical benefit. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 826-831.	0.9	11
72	Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial. <i>Digestive and Liver Disease</i> , 2011, 43, 459-464.	0.4	10

#	ARTICLE	IF	CITATIONS
73	Multifocal Pyoderma Gangrenosum Resistant to Infliximab in Active Ulcerative Colitis: Don't Forget the Role of Cyclosporin. <i>Inflammatory Bowel Diseases</i> , 2012, 18, E1594-E1595.	0.9	10
74	Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients. <i>Journal of Clinical Virology</i> , 2015, 66, 103-106.	1.6	10
75	Is splenectomy a treatment option for aseptic abscesses in patients with Crohn's disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 1314-1316.	0.8	9
76	The METEOR Trial: The Burial of Methotrexate in Ulcerative Colitis?. <i>Gastroenterology</i> , 2016, 151, 211-212.	0.6	9
77	Incidence of HSV and HPV with azathioprine. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 444-445.	8.2	8
78	Does glatiramer acetate provoke hepatitis in multiple sclerosis?. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 266-268.	0.9	8
79	Selective Use of Combination Therapy in Patients With Infliximab-resistant Inflammatory Bowel Disease: Data From a Tertiary Referral Center. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 914.	2.4	8
80	Randomized Controlled Trials in Perianal Crohn's Disease. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 297-302.	0.4	8
81	CA 19-9 to Rule Out Pancreatic or Biliary Cancer Among Patients with Cholestasis: An Unsuitable Test?. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1125-1127.	1.1	7
82	Placebo therapy in Crohn's disease. <i>European Journal of Internal Medicine</i> , 2009, 20, 572-578.	1.0	7
83	Marked impact of IL28B genotype in the natural clearance of hepatitis C virus in patients with haemoglobinopathies. <i>British Journal of Haematology</i> , 2011, 154, 659-661.	1.2	7
84	An update on medical management on Crohn's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 63-78.	0.9	7
85	The Selective Use of Combination Therapy in Patients with Inflammatory Bowel Disease Resistant to Anti-TNF: to Whom, How and How Long?. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1451-1451.	0.6	7
86	JC Virus, Helicobacter pylori, and Oesophageal Achalasia: Preliminary Results from a Retrospective Case-Control Study. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1433-1434.	1.1	6
87	An Unusual Presentation of Zollinger-Ellison Syndrome. <i>Case Reports in Gastroenterology</i> , 2013, 7, 1-6.	0.3	6
88	Advanced endoscopic imaging for surveillance for dysplasia and colorectal cancer in inflammatory bowel disease: Could the pathologist be further helped?. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 26.	0.5	6
89	Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. <i>Digestive and Liver Disease</i> , 2016, 48, 1314-1317.	0.4	6
90	Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF inhibitors and conventional immunosuppressants. <i>Digestive and Liver Disease</i> , 2017, 49, 157-162.	0.4	6

#	ARTICLE	IF	CITATIONS
91	Risk of Pneumonia Caused by <i>Pneumocystis jiroveci</i> in Inflammatory Bowel Disease: The Role of Concomitant Pulmonary Comorbidities. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 571-572.	2.4	6
92	JC Virus and Lung Adenocarcinoma: Fact or Myth?. <i>Anticancer Research</i> , 2017, 37, 3311-3314.	0.5	6
93	Could growth hormone play a role in Peutz Jeghers syndrome?. <i>Medical Hypotheses</i> , 2013, 81, 966-967.	0.8	5
94	Increased risk of pneumonia among patients with inflammatory bowel disease: A comparison between patients treated with biologic therapies and with conventional drugs. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e405-e406.	0.6	5
95	Infliximab, azathioprine or combination therapy in the treatment of active Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2010, 4, 709-712.	1.4	4
96	Smoking therapy may be an extreme cure in exsmokers with steroid-dependent and resistant ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2213.	0.9	4
97	Familial mediterranean fever gene (MEVF) mutations in Crohn's disease in a Mediterranean area. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1313.	0.9	3
98	Prevalence of CARD15/NOD2 Mutations in the Sicilian Population. <i>American Journal of Gastroenterology</i> , 2008, 103, 248-249.	0.2	2
99	Infliximab prevents Crohn's disease recurrence after ileal resection. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 231-234.	1.4	2
100	Oral valganciclovir for colonic dilatation in ulcerative colitis associated with human cytomegalovirus infection. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 727-728.	0.9	2
101	Unusual perforation after balloon dilation in a Crohn's disease patient: Report of a case. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 269-270.	0.6	2
102	An unusual presentation of T-lymphoma in a Crohn's disease patient treated with combo therapy: We are willing to take a risk of serious adverse events for a doubtful benefit?. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 954-955.	0.6	2
103	Budesonide MMX and Mesalamine to Induce Remission in Patients With Ulcerative Colitis. <i>Gastroenterology</i> , 2013, 144, e23.	0.6	2
104	Comparing medical treatments for Crohn's disease. <i>Journal of Comparative Effectiveness Research</i> , 2013, 2, 135-149.	0.6	2
105	Methodology for high-quality studies on course and prognosis of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 3800.	1.4	2
106	Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: Clinical Response without Endoscopic Response. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 1009-1010.	0.9	1
107	An open safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1113-1123.	0.9	1
108	Early postoperative recurrence of severe crohn's disease, with colonic involvement and associated human cytomegalovirus infection, treated with oral valganciclovir and adalimumab. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E43-E44.	0.9	1

#	ARTICLE	IF	CITATIONS
109	Combined treatment with adalimumab and surgery in a patient with steroid-dependent Crohn's disease complicated by perianal disease. <i>Digestive and Liver Disease Supplements</i> , 2010, 4, 34-37.	0.2	0
110	A rare case of ulcerative proctitis associated with type B lymphomatoid papulosis and superimposed human cytomegalovirus infection. <i>International Journal of Dermatology</i> , 2012, 51, 838-839.	0.5	0
111	Course of Crohn's Disease. , 2016, , 31-42.		0
112	Medical Treatment of Perianal Crohn's Disease. , 2016, , 49-58.		0